Here are nine facts:
1. SpineGuard’s sales increased 43 percent to €6.3 million, up from €4.4 million in 2014.
2. In 2015, the company sold 7,449 PediGuard units, compared to 6,063 units in 2014.
4. Of the PediGuard units sold, the company sold 4,306 in the United States.
5. The gross margin reached 84.5 percent, compared to 85.2 percent the year prior.
6. SpineGuard’s net loss was €3.9 million in 2015, compared to €4.5 million in 2014.
7. The company experienced a 13 percent increase in operating expenses, hitting €9.3 million.
8. Cash and cash equivalents registered at €3.2 million in 2015, compared to €2.5 million in 2014.
9. The company secured financing of €10.5 million.
Read SpineGuard’s full financial report here.
“The strong growth in the USA, Europe and Japan, as well as the regulatory approval in China, continue to validate the outstanding clinical value of the PediGuard range,” said Pierre Jérôme, CEO and co-founder, SpineGuard.
More articles on devices:
Amedica successfully uses 3D printing to create silicon nitride devices: 4 things to know
13 new device launches & releases — March 23, 2015
Medtronic, NuVasive among top 7 vendors in US intraoperative neuromonitoring market
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
